SpringWorks Therapeutics Inc (SWTX)
SpringWorks Therapeutics a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing medicines for underserved patient populations suffering from devastating rare diseases and cancer. Co.'s product candidate, nirogacestat, is an oral, small molecule gamma secretase inhibitor in development as a monotherapy for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor. Co.'s second product candidate is mirdametinib, an oral, small molecule MEK inhibitor initially in development for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas.
SWTX SEC Filing Email Alerts Service
| Company Name: |
SpringWorks Therapeutics Inc |
| Website: |
www.springworkstx.com |
| Sector: |
Biotechnology |
| Number of ETFs Holding SWTX: |
29 |
| Total Market Value Held by ETFs: |
$441.30M |
| Total Market Capitalization: |
$3.20B |
| % of Market Cap. Held by ETFs: |
13.78% |
|
|
April 19, 2024 • 11:49 AM Eastern
Strong Buy (4.00 out of 4)
100th percentile
|
|
Free SWTX Email Alerts:
